First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025LYTENAVA™ is the first and only approved ...

An announcement from Outlook Therapeutics ( (OTLK) ) is now available.

Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its target price reduced by BTIG Research from $50.00 to $9.00 in a ...

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report ...

Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...

On Friday, Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $1.97 which represents a slight increase of $0.27 or 15.88% from the prior close of $1.7. The stock opened at $1 ...

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

Outlook Therapeutics Inc. (NASDAQ:OTLK) revealed preliminary topline results of NORSE EIGHT, the second of two clinical ...

BTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The ...

On Wednesday, Outlook Therapeutics Inc (OTLK) stock saw a decline, ending the day at $1.7 which represents a decrease of $-3.19 or -65.24% from the prior close of $4.89. The stock opened at $0.98 and ...

Outlook Therapeutics (OTLK) stock plunges 81% after clinical trial failure for its wet AMD therapy, ONS-5010. Read more here.

Fintel reports that on December 2, 2024, Wells Fargo upgraded their outlook for Kymera Therapeutics (NasdaqGM:KYMR) from ...